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Background: Many Protein Data Bank (PDB) users assume that the deposited structural models are of high quality
but forget that these models are derived from the interpretation of experimental data. The accuracy of atom
coordinates is not homogeneous between models or throughout the same model. To avoid basing a research
project on a flawed model, we present a tool for assessing the quality of ligands and binding sites in
crystallographic models from the PDB.
Results: The Validation HElper for LIgands and Binding Sites (VHELIBS) is software that aims to ease the validation
of binding site and ligand coordinates for non-crystallographers (i.e., users with little or no crystallography
knowledge). Using a convenient graphical user interface, it allows one to check how ligand and binding site
coordinates fit to the electron density map. VHELIBS can use models from either the PDB or the PDB_REDO
databank of re-refined and re-built crystallographic models. The user can specify threshold values for a series of
properties related to the fit of coordinates to electron density (Real Space R, Real Space Correlation Coefficient and
average occupancy are used by default). VHELIBS will automatically classify residues and ligands as Good, Dubious or
Bad based on the specified limits. The user is also able to visually check the quality of the fit of residues and ligands
to the electron density map and reclassify them if needed.
Conclusions: VHELIBS allows inexperienced users to examine the binding site and the ligand coordinates in
relation to the experimental data. This is an important step to evaluate models for their fitness for drug discovery
purposes such as structure-based pharmacophore development and protein-ligand docking experiments.
Keywords: Electron density map, Binding site structure validation, Ligand structure validation, Protein structure
validation, PDB, PDB_REDOBackground
The 3D structure of proteins depends on their amino
acid sequence [1] but cannot be predicted based solely
on that sequence, except for relatively small proteins [2].
As the structure of a molecule cannot be observed
directly, a model of the structure must be constructed
using experimental data. These data can be obtained
through different methods, such as X-ray crystallography,
NMR spectroscopy or electron microscopy. However,* Correspondence: gerard.pujadas@urv.cat
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the Creative Commons Attribution License (h
distribution, and reproduction in any mediumnone of these methods allows for the direct calculation
of the structure from the data. In X-ray crystallography,
the most widely applied method, the crystallographic
diffraction data are used to construct a three-dimen-
sional grid that represents the probability for electrons
to be present in specific positions in space, the so-called
electron density (ED) map. The ED shows the average
over many (typically between 1013 and 1015) molecules
arranged in a periodic fashion in crystals and is the
average over the time of the X-ray experiment [3]. This
ED is then interpreted to construct an atomic model of
the structure. The model is just a representation of the
crystallographic data and other known information
about the structure, such as the sequence, bond lengths
and angles. Different models, such as the thousands of
models in the Protein Data Bank (PDB) [4], represent theistry Central Ltd. This is an Open Access article distributed under the terms of
ttp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the quality of experimental data (for example, the reso-
lution limit of the diffracted X-rays) varies significantly.
Due to the interpretation step during modeling, which
is inevitably subjective [5,6], it is very important to see
if a model fits reasonably to the ED that was used to
construct it, to ensure its reliability. For drug discovery
and design purposes, the model quality of the protein
binding sites and of the ligands bound to them are of
particular interest, while the overall model quality or
the quality of the model outside the binding site are
not directly relevant.
A good way to assess how well a subset of atomic coor-
dinates fits the experimental electron density is the Real
Space R-value (RSR) [7], which has been recommended by
the X-ray Validation Task Force of the Worldwide PDB
[8,9]. The RSR measures a similarity score between the
2mFo-DFc and the DFc maps. The real-space correlation
coefficient (RSCC) [6] is another well-established measure
of model fit to the experimental data. The use of the ED
to validate the model will not catch all possible problems
in the model [10], but it can show whether the model fits
the data from which it was created.
VHELIBS aims to enable non-crystallographers and
users with little or no crystallographic knowledge to
easily validate protein structures before using them in
drug discovery and development. To that end, VHELIBS
features a Graphical User Interface (GUI) with carefully
chosen default values that are valid for most situations but
allows parameters to be easily tuned for more advanced
users. A tool named Twilight [11,12] has recently been
published to evaluate ligand density. However, while
VHELIBS focuses on assessing both the ligands and
binding sites to aid model evaluation for drug discovery
purposes, Twilight is ligand-centric and focuses on high-
lighting poorly modeled ligands. VHELIBS also enables
the user to choose between the models from either the
PDB [4,13] or the PDB_REDO [14] databanks. Using
PDB_REDO as the data source can have substantial
benefits over using the PDB. PDB_REDO changes mo-
dels both by re-refinement, incorporating advances in
crystallographic methods since the original structure
model (the PDB entry) was constructed, and by limited
rebuilding, mainly of residue side chains [15], improv-
ing the fit of models to the ED [16].
Implementation
VHELIBS validates the binding site and ligand against
the ED in a semi-automatic way, classifying them based
on a score of Good, Bad or Dubious. This score is calcu-
lated by taking several parameters into account (RSR,
RSCC, and average occupancy by default, but more can
be used). After performing the automatic analysis and
classification of a target’s binding site and ligand, it thenenables the user to graphically review and compare them
with their ED in order to make it easier to properly clas-
sify any structure labeled ‘dubious’ or to re-classify any
other structure based on actual visual inspection and
comparison of the ED with the model.
VHELIBS is mainly implemented using Python under
Jython [17], with some critical parts implemented in
Java. It uses Jmol [18] for the 3D visualization of models
and EDs. Electron density maps are retrieved from the
EDS [19,20] or from the PDB_REDO databank, which
are updated weekly with new data from the PDB. Models
are downloaded from either the PDB or PDB_REDO
according to the user settings.
Description of the algorithm
VHELIBS takes as input a user-provided list of either
PDB [13] or UniProtKB [21] codes (which are mapped
to their corresponding PDB codes). The codes in these
lists can be entered directly from the GUI or provided in
a text file.
For each of these PDB codes, statistical data are re-
trieved from the EDS or from the PDB_REDO, depending
on the source of the models being analyzed (i.e., EDS data
for models downloaded from the PDB and PDB_REDO
data for models downloaded from the PDB_REDO).
Ligands bound with residues or molecules included in
the ‘blacklist’ exclusion list (see below) with a bond
length < 2.1 Å are rejected. Those ligands bound to
molecules in the ‘non-propagating’ exclusion list (which
can be modified by the user and by default contains
mainly metal ions) are not rejected. The exclusion lists
are composed of the most common solvent molecules
and other non-ligand hetero compounds often found in
PDB files, as well as some less common solvents and
molecules that were found to have very simple binding
sites (e.g., a binding site consisting of just 1–2 residues).
We also incorporated the buffer molecules from Twilight’s
list [11,12]. The exclusion list from BioLip [22] was also
considered, but deemed too restrictive.
Once the ligands are determined, all the residues
nearer than a specified distance (4.5 Å by default) are
considered to be part of the binding site of that ligand.
Then, every ligand and binding site residue is given a
score and classified by that score based on the following
algorithm (see also Figure 1):
 For each residue and component of each ligand
and each binding site, the initial score is defined
to be 0.
 For each unmet user-specified condition, the score
is increased by 1. The user specified conditions are
the value thresholds for several different properties
of the model and the data (i.e., RSR, RSCC,
occupancy-weighted B factor, R-free, resolution and
Figure 1 Automatic ligand and binding site classification. This diagram shows the process by which the ligands and binding sites of each
PDB/PDB_REDO model are classified based on how well the model fits the ED.
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subset of these properties).
 If the score remains 0, the ligand/residue is labeled
as Good.
 If the score is greater than the user-defined
tolerance value, the ligand/residue is labeled as Bad.
 If the score is between 0 and the user-defined
tolerance value, the ligand/residue is labeled as
Dubious.
 At the end of all evaluations, the binding site and
the ligand (for ligands with more than 1 ‘residue’, i.e.,
those composed of more than one hetero compound
in the PDB file) are labeled according to the worst
score of their components (i.e., a binding site with a
Bad residue will be labeled as Bad regardless of how
the rest of the residues are labeled, and a binding
site can only be labeled as Good when all its
residues are Good).
The results from this classification are saved to a CSV
file (the results file), which can be opened by any major
spreadsheet software and can then be filtered as desired
(for Good ligands, for Good binding sites or for both). A
file with a list of all the rejected PDB structures andligands and the reason for the rejection is also generated
with the results file.
After this automatic classification of ligands and bin-
ding sites is complete, the user can visually inspect the
results in order to see whether a binding site or ligand
labeled as Dubious can actually be marked as Good
(Figures 2 and 3). The default visualization settings
provide users of VHELIBS with the appropriate frame
to easily reclassify Dubious residues and ligands either
as Good or Bad:
 binding site residues are shown by default in white
and with a wireframe style in order to show the
context where the possible reclassification is
evaluated.
 coordinates to examine for veracity are shown in
ball and stick style and colored according to their
B-factor.
 ligand coordinates are shown in ball and stick style
and colored in magenta (but can be colored
according to their B-factor if they need to be
examined).
 the ED for coordinates to examine is shown in
yellow.
Figure 2 Example of a Good ligand with a Dubious binding site. Here, we can see a ligand (S14 B1002 in PDB entry 2FJP [23]) and its
binding site, from the analysis of DPP4_HUMAN using the Default (PDB) profile. The only dubious residue from the binding site is the one with
the yellow ED represented as ball and stick and colored by B-factor.
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to the visualization (in cyan) if necessary.
 the ED for the ligand can be shown separately
(in red).
Hence, with this visualization frame, the user has all
the information he/she needs in order to decide, for
instance, whether (a) dubious binding site coordinates
could be relevant for protein-ligand docking results (if
the dubious coordinates face away from the ligand, it
is reasonable to think that their accuracy does not
affect protein-ligand docking results); and (b) ligand
coordinates that were classified as Bad or Dubious by
the automatic analysis can be changed to Good if the
experimental pose is the only possibility for its corre-
sponding ED (this can occur with non-flexible rings
that have only partial ED for their atoms). In the online
documentation (https://github.com/URVnutrigenomica-
CTNS/VHELIBS/wiki) [25], there is more information on
this and some practical rules for guiding such an evalu-
ation. Of course, the visualization of the binding site,
the ligand and coordinates to examine (dubious or bad
residues and ligands) and their respective EDs can becustomized in several ways through the GUI, e.g., by
changing atom colors and styles or the contour level
and radius of the EDs.
VHELIBS can be used with different running conditions
(i.e., with different profiles). The values of the default
profiles [i.e., Default (PDB) and Default (PDB_REDO)]
were chosen after careful visualization and comparison of
models with their EDs, giving a default minimum RSCC
of 0.9, a minimum average occupancy of 1.0, a maximum
RSR of 0.4 and a maximum good RSR of 0.24 for PDB
and 0.165 for PDB_REDO. The different RSR cut-offs
for the PDB and PDB_REDO are the result of RSR being
calculated using different software in the EDS (which
uses MAPMAN [26]) and in PDB_REDO (which uses
EDSTATS [27]). The third provided profile, Iridium, is
based on the values used in the construction of the Iridium
set [28]. This profile is only provided as an example of how
easy it is to adapt VHELIBS to use other values found in
the literature. Note however that VHELIBS will yield
slightly different results from those in the Iridium set, be-
cause VHELIBS uses the EDs and statistical data from EDS
or PDB_REDO, while the authors of the Iridium set calcu-
late all the data using different software and different EDs.
Figure 3 Example of a dubious ligand with a bad binding site. Here, we can see a ligand (AZV A 1 in PDB entry 3Q8W [24]) and its binding
site from the same analysis as in Figure 2. As can be seen, some residues from this binding site hardly fit their ED (in yellow). The ligand mostly
fits its ED, but it still has some discrepancies.
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 Many different parameters can be used to filter good
models, and their threshold values can be adjusted
by the user. Contextual help informs the user about
the meaning of the different parameters.
 VHELIBS comes with three profiles, and the user
can create custom profiles and export them for
further use or sharing.
 VHELIBS has the ability to work with an unlimited
number of PDB or UniProtKB [29] codes (all the
PDB codes in each UniProtKB entry are analyzed).
 VHELIBS has the ability to choose between models
from PDB_REDO or from the PDB.
 VHELIBS runs in the Java Virtual Machine, which
makes it operating-system independent.
 VHELIBS consists of a single jar file, needing no
installation. There are no dependencies other
than Java.
 The user can load a results file from a previous
analysis; one can let a huge analysis run during
lunch or overnight and then review the results at
any later time. A user does not need to be familiar with any other
software (although familiarity with Jmol [18] will
help the user to make sophisticated custom views).
PDB_REDO changes to support VHELIBS
The PDB_REDO databank was upgraded to have per-
residue RSR and RSCC values and downloadable EDs
in the CCP4 [30] format for each entry. These ready-
made maps make electron density visualization possible
not only in VHELIBS but also in PyMOL [31] (for
which a plugin is available via the PDB_REDO website).
To assess how much of the previously observed model
improvement in PDB_REDO [16] is applicable to ligands
and their binding pocket, we implemented two new lig-
and validation routines in the PDB_REDO pipeline: (1)
EDSTATS [27] calculates the fit of the ligand with the
ED; and (2) YASARA [32] calculates the heat of forma-
tion of the ligand (which is used as a measure of geo-
metric quality) and the interactions of the ligand with its
binding pocket. The interactions measured in YASARA
include the number of atomic clashes (bumps), the num-
ber and total energy of hydrogen bonds, and the number
and strength of hydrophobic contacts, π-π interactions,
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contacts, π-π interactions, and cation-π interactions are
based on knowledge-based potentials [33] in which each
individual interaction has a score between 0 and 1.
Results and discussion
We performed an analysis of the ligand quality scores in
the PDB and PDB_REDO for more than 16,500 ligands
(compounds described by the PDB as a ‘non-polymer’
and not chemically linked to the protein, with common
crystallization additives, such as sulfate and glycerol, ex-
cluded) in more than 5,900 structures, and the results
are summarized in Table 1. The results show that li-
gands in PDB_REDO are better in terms of fit to the ED
(better RSR and RSCC) and have more favorable geom-
etry (lower heat of formation). Although the interactions
with binding sites improve, the changes are very small,
except for the reduction in atomic clashes. This is to be
expected, as ligand binding sites are typically the most
important part of a structure model, and much attention
is paid to ensure that the model is correct in that area.
Nevertheless, in individual cases the improvement can
be great enough to change a Dubious ligand in a Bad
binding site to a Good ligand in a Good binding site
(Figure 4).
All ligands and binding sites present in both the EDS
and the PDB_REDO databanks were analyzed using the
appropriate default profiles [Default (PDB) and Default
(PDB_REDO)]. The results are summarized in Table 2
(for the binding sites) and Table 3 (for the ligands). In
the case of the binding sites, the Good binding sites inTable 1 Average validation scores for ligands in PDB
and PDB_REDO




RSR c 0.120 0.104
RSCC c 0.90 0.92




Hydrophobic contact strength d,e 16.20 16.43
π-π interaction strength d,e 1.26 1.28
Cation-π interaction strength d,e 1.17 1.19
Number of atomic clashes d 9.1 7.9
a A smaller value is better for RSR, heat of formation (strained ligand
conformations give higher values), hydrogen bonding energy and number of
atomic clashes. A larger value is better for RSCC, hydrophobic contact
strength, π-π interaction strength and cation-π interaction strength.
b Average over 16,904 ligands (13,703 for heat of formation) in 5,932
structure models.
c Calculated using EDSTATS [27].
d Calculated using YASARA [32] using the atomic coordinates as is.
e The average reported is the average sum of all interactions for a
single ligand.the EDS account for 19%, while in PDB_REDO, they ac-
count for 36%, although only 67% of the Good binding
sites in the EDS are classified as Good for PDB_REDO,
and some of them are even classified as Bad. In the case
of the ligands, however, the improvement in classifica-
tion from the PDB_REDO is far more significant: Good
ligands increase from 31% from the EDS to 64% from
PDB_REDO, with most of the Good ligands from the
EDS still classified as Good from PDB_REDO (95%); Bad
ligands are dramatically reduced from 43% for EDS to
4% from PDB_REDO, having most of these Bad ligands
from EDS classified as Good from the PDB_REDO.
Interestingly, our results suggest that by default, a typical
VHELIBS user should choose the Default (PDB_REDO)
profile instead of the Default (PDB) one. From the
16,830 binding sites that are labeled as Good by either of
the default profiles, 85% of them are identified by the
Default (PDB_REDO) profile [in contrast with only 46%
being identified by the Default (PDB) profile]. This is
even more remarkable when the ligands are considered:
from the 26,028 ligands labeled as Good by either of the
default profiles, 97% of them are identified by the De-
fault (PDB_REDO) profile, and only 48% are identified
by the Default (PDB).
To demonstrate how VHELIBS can be used, we chose
as a test case the human Dipeptidyl peptidase 4 (DPP-
IV). We first used the corresponding UniProtKB name,
DPP4_HUMAN, with the Default (PDB_REDO) pro-
file. There are 74 different PDB structures listed in the
UniProtKB entry for this protein. The automatic analysis
of all of these structures took an average of 2 min 0.43 s
on an AMD FX-8150 machine running Ubuntu 12.04.1
LTS amd64 and Java (OpenJDK) 1.6.0_24, with some of
the time spent downloading data from the PDB_REDO
(with cached PDB_REDO data, and thus without down-
loading it, the average is 1 min 15.78 s). Out of the ori-
ginal 74 PDB structures, 10 were rejected because there
were no PDB_REDO data available for them (1J2E,
1NU6, 1NU8, 1R9M, 1R9N, 1RWQ, 1WCY, 2BUB, 2JID
and 2QKY). Rejection occurs most often when a PDB
entry lacks experimental X-ray reflection data, which is
the case for the ten structures listed. From the re-
maining 64 structures, 44 had no ligands, leaving 20
structures. These 20 PDB_REDO models showed 450
possible ligand-binding site pairs, of which 9 were re-
jected because the ligand was covalently bound to a resi-
due, and 366 were rejected because the ligand was either
on the exclusion list or covalently bound to a ligand on
that list. Most of these rejected ligand-binding sites
include molecules such as sulfate/SO4, which are marked
as hetero compounds by the PDB, covalently bound
ligands (e.g., mannose/MAN in 2BGN), or metal ions
(e.g., sodium or mercury) that are not usually used for
drug discovery purposes. There were 75 valid ligand-
Figure 4 The guanosine-5′-monophosphate binding site in chain C of PDB entry 1A97 [34] is an example of a ligand and binding site
flagged as dubious and bad in the PDB, respectively (left panel: upper with cyan ED for the binding site and red ED for the ligand;
lower with default view: yellow ED for Dubious and Bad residues), but scored as Good in PDB_REDO (right panel: upper with cyan ED
for the binding site and red ED for the ligand; lower with previously bad or dubious residues with orange ED). The RSR and RSCC of the
ligand improve from 0.154 to 0.065 and from 0.86 to 0.97, respectively. Two extra hydrogen bonds are introduced, improving the total hydrogen
bonding energy from −157 kJ/mol to −199 kJ/mol. The all-atom root mean square deviation of the ligand is 0.6 Å. Of the residues in the binding
site, arginine 69 and the boric acid molecule improve most significantly in terms of fit to the ED.
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gands, 57 as Good binding sites and 43 as Good ligand
and binding site (Table 4). With 55 Good ligands and
57 Good binding sites (43 of them being Good binding
sites with Good ligands), there should be enough Good
structures for most uses; it would not be necessary to
review the Dubious ones. However, if this were not the




EDS Good 5,145 1,600 926 7,671
Bad 5,500 3,727 8,395 17,622
Dubious 3,659 2,953 7,915 14,527
14,304 8,280 17,236 39,820
This table shows how binding sites were classified when coming from the EDS
or from the PDB_REDO databank.them for the specific purposes. Figure 2 shows one ex-
ample of a Good ligand with a Dubious binding site,
whereas Figure 3 shows a Dubious ligand with a Bad
binding site. The user can also review the Good struc-
tures if he or she is looking for false positives, or review
the Bad ones in the hope of finding good enough struc-
tures there (which is very unlikely using the default




EDS Good 11,741 16 662 12,419
Bad 9,819 1,206 6,098 17,123
Dubious 3,790 229 6,259 10,278
25,350 1,451 17,236 39,820
This table shows how ligands were classified when coming from the EDS or
from the PDB_REDO databank.
Table 4 Number of complexes classified as Good, Bad or
Dubious after applying VHELIBS to 75 ligand/DPP-IV




Ligand Good 43 0 12 55
Bad 0 0 0 0
Dubious 14 0 6 20
57 0 18 75
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very helpful:
 VHELIBS can be used to choose structures to use
for a protein-ligand docking: with VHELIBS, the
user can choose the structures with the best-
modeled binding sites.
 VHELIBS can be used to choose structures
where both the binding site and the ligand are
well modeled, in order to validate the
performance of different protein-ligand docking
programs. This could make it possible to obtain
a new gold standard for protein/ligand
complexes that could be used for the validation
of docking software and that could be
significantly larger and more diverse than those
currently being used (i.e., the Astex Diverse Set
[35] and the Iridium set [28]).
 VHELIBS can be used to choose structures where
both the binding site and the ligand are well
modeled to obtain reliable structure-based
pharmacophores that select the relevant target
bioactivity-modulating intermolecular interactions.
This is important in drug-discovery workflows for
finding new molecules with similar activity to the
co-crystallized ligand.
 VHELIBS can be used to obtain well-modeled ligand
coordinates in order to evaluate the performance of
3D conformation-generator software that claims to
be able to generate bioactive conformations.Conclusions
VHELIBS allows the user to easily check the fit of
models to the ED for binding sites and ligands without
additional scripting or console commands for each
structure. Moreover, our study allows us to conclude
that in general, binding site and ligand coordinates de-
rived from PDB_REDO structures are more reliable than
those obtained directly from the PDB and therefore
highlights the contribution of the PDB_REDO database
to the drug-discovery and development community.Availability and requirements
Project name: VHELIBS (Validations Helper for Ligands
and Binding Sites).
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License: GNU AGPL v3.
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other than those specified by the license (same as for
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